title: Translational neuroimaging of the CNS: novel pathways to drug development.
abstract: Scientists engaged in drug discovery and development face many critical issues along the road to identifying the best drug candidates to bring forward for testing in patients. In neuroscience, these challenges can involve particularly demanding questions regarding target engagement, the predict ability of endpoints in animal models, new disease model validation, CNS penetration, and the identification of pharmacodynamic markers. For neurological conditions such as Alzheimer's disease, clinical trials of novel drugs that may modify the course of disease, rather than targeting specific symptoms, add extra layers of complexity. Major studies designed to track the course of a disease increasingly depend on noninvasive, translational imaging. In this brief review, we highlight examples of the new wave of neuroimaging studies that engender useful biomarkers of disease for translational research.
authors.affiliation: Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064.
authors.forename: Gerard B
authors.initials: GB
authors.lastname: Fox
authors.forename: Chih-Liang
authors.initials: CL
authors.lastname: Chin
authors.forename: Feng
authors.initials: F
authors.lastname: Luo
authors.forename: Mark
authors.initials: M
authors.lastname: Day
authors.forename: Bryan F
authors.initials: BF
authors.lastname: Cox
mesh_terms: D000818:Animals; D002490:Central Nervous System / Q000000981:diagnostic imaging*; D003943:Diagnostic Techniques, Neurological; D006801:Humans; D007091:Image Processing, Computer-Assisted / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000473:pathology*; D049268:Positron-Emission Tomography / Q000379:methods; D011859:Radiography; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods